Literature DB >> 20690034

Soluble receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation.

Chun-Hsiung Chen1, Hung-An Chen, Hsien-Tzung Liao, Chin-Hsiu Liu, Chang-Youh Tsai, Chung-Tei Chou.   

Abstract

The objective of the study was to investigate the role of receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin (OPG) in ankylosing spondylitis (AS). Serum levels of soluble RANKL (sRANKL) and OPG were measured in 42 AS patients and 26 healthy controls. We evaluated the AS patient's disease activity, functional ability, global assessment, and physical mobility and tested markers of systemic inflammation, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) levels. Serum levels of sRANKL [mean (SD), 4.75 (1.88) vs. 3.70 (1.14) pmol/l, p = 0.015] and OPG [mean (SD), 5.18 (1.19) vs. 4.52 (0.85) pmol/l, p = 0.026] were significantly higher in the 42 AS patients than the 26 healthy controls. Interestingly, serum OPG levels correlated significantly with ESR (r = 0.417, p = 0.007), CRP (r = 0.524, p < 0.001), tragus-to-wall distance (r = 0.556, p < 0.001), fingertip-to-floor distance (r = 0.423, p = 0.007), and occiput-to-wall distance (r = 0.465, p = 0.002) and correlated inversely with modified Schober index (r = -0.525, p = 0.001), cervical rotation (r = -0.403, p = 0.022), lateral lumbar flexion (r = -0.587, p < 0.001), and chest expansion (r = -0.553, p < 0.001). Moreover, in the AS patients with higher (> or =4.925 pmol/l, n = 21) serum OPG levels, there were significant increases in the tragus-to-wall distance (p = 0.007), fingertip-to-floor distance (p = 0.023), and CRP levels (p = 0.014) and decreased in the modified Schober index (p = 0.012), lateral lumbar flexion (p = 0.019), and chest expansion (p = 0.005). Serum levels of sRANKL and OPG are increased in the AS patients and may participate in the disease process of AS. Production of OPG has association with poor physical mobility and may reflect systemic inflammation in AS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20690034     DOI: 10.1007/s10067-010-1543-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  26 in total

1.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

2.  The Bath Ankylosing Spondylitis Patient Global Score (BAS-G).

Authors:  S D Jones; A Steiner; S L Garrett; A Calin
Journal:  Br J Rheumatol       Date:  1996-01

3.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Authors:  S van der Linden; H A Valkenburg; A Cats
Journal:  Arthritis Rheum       Date:  1984-04

4.  Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis.

Authors:  L C Hofbauer; M Schoppet; M Christ; J Teichmann; U Lange
Journal:  Rheumatology (Oxford)       Date:  2006-03-30       Impact factor: 7.580

5.  Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis.

Authors:  Helmut Franck; Thomas Meurer; Lorenz Christian Hofbauer
Journal:  J Rheumatol       Date:  2004-11       Impact factor: 4.666

6.  Relationship of elevated osteoprotegerin with insulin resistance, CRP, and TNF-alpha levels in men with type 2 diabetes.

Authors:  Subhashini Yaturu; Justin Rains; Sushil K Jain
Journal:  Cytokine       Date:  2008-09-11       Impact factor: 3.861

7.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Authors:  A Calin; S Garrett; H Whitelock; L G Kennedy; J O'Hea; P Mallorie; T Jenkinson
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

Review 8.  [Osteoporosis in ankylosing spondylitis].

Authors:  E Toussirot; D Wendling
Journal:  Presse Med       Date:  1996-04-27       Impact factor: 1.228

9.  Elevated serum receptor activator of NFkappaB ligand (RANKL), osteoprotegerin (OPG), matrix metalloproteinase (MMP)3, and ProMMP1 in patients with juvenile idiopathic arthritis.

Authors:  Pradip Kumar Sarma; Ramnath Misra; Amita Aggarwal
Journal:  Clin Rheumatol       Date:  2007-08-17       Impact factor: 2.980

10.  The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation.

Authors:  Bernard Vandooren; Tineke Cantaert; Troy Noordenbos; Paul P Tak; Dominique Baeten
Journal:  Arthritis Rheum       Date:  2008-03
View more
  19 in total

Review 1.  Biomarker development for axial spondyloarthritis.

Authors:  Matthew A Brown; Zhixiu Li; Kim-Anh Lê Cao
Journal:  Nat Rev Rheumatol       Date:  2020-06-30       Impact factor: 20.543

Review 2.  Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis.

Authors:  John D Reveille
Journal:  Clin Rheumatol       Date:  2015-05-05       Impact factor: 2.980

Review 3.  Relationship between serum RANKL and RANKL in bone.

Authors:  D M Findlay; G J Atkins
Journal:  Osteoporos Int       Date:  2011-08-18       Impact factor: 4.507

4.  Relationship of serum osteoprotegerin with arterial stiffness, preclinical atherosclerosis, and disease activity in patients with ankylosing spondylitis.

Authors:  Münevver Serdaroğlu Beyazal; Turan Erdoğan; Aysegül Kücükali Türkyılmaz; Gül Devrimsel; Medine Cumhur Cüre; Mehmet Beyazal; Ismail Sahin
Journal:  Clin Rheumatol       Date:  2016-02-04       Impact factor: 2.980

Review 5.  Bone Involvement in Patients with Spondyloarthropathies.

Authors:  Willem Lems; Corinne Miceli-Richard; Judith Haschka; Andrea Giusti; Gitte Lund Chistensen; Roland Kocijan; Nicolas Rosine; Niklas Rye Jørgensen; Gerolamo Bianchi; Christian Roux
Journal:  Calcif Tissue Int       Date:  2022-01-23       Impact factor: 4.333

6.  Circulating Levels of Soluble Receptor Activator of NF- κ B Ligand and Matrix Metalloproteinase 3 (and Their Antagonists) in Asian Indian Patients with Ankylosing Spondylitis.

Authors:  Varun Dhir; Rajni Srivastava; Amita Aggarwal
Journal:  Int J Rheumatol       Date:  2013-09-01

7.  Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis.

Authors:  Ali Taylan; Ismail Sari; Baris Akinci; Safak Bilge; Didem Kozaci; Servet Akar; Ayfer Colak; Hulya Yalcin; Necati Gunay; Nurullah Akkoc
Journal:  BMC Musculoskelet Disord       Date:  2012-10-02       Impact factor: 2.362

8.  Serum osteoprotegerin is increased and predicts survival in idiopathic pulmonary arterial hypertension.

Authors:  Robin Condliffe; Josephine A Pickworth; Kay Hopkinson; Sara J Walker; Abdul G Hameed; Jay Suntharaligam; Elaine Soon; Carmen Treacy; Joanna Pepke-Zaba; Sheila E Francis; David C Crossman; Christopher M H Newman; Charles A Elliot; Allison C Morton; Nicholas W Morrell; David G Kiely; Allan Lawrie
Journal:  Pulm Circ       Date:  2012 Jan-Mar       Impact factor: 3.017

Review 9.  How to translate basic knowledge into clinical application of biologic therapy in spondyloarthritis.

Authors:  Chung-Tei Chou
Journal:  Clin Dev Immunol       Date:  2013-06-11

10.  RANKL from bone marrow adipose lineage cells promotes osteoclast formation and bone loss.

Authors:  Yan Hu; Xiaoqun Li; Xin Zhi; Wei Cong; Biaotong Huang; Huiwen Chen; Yajun Wang; Yinghua Li; Lipeng Wang; Chao Fang; Jiawei Guo; Ying Liu; Jin Cui; Liehu Cao; Weizong Weng; Qirong Zhou; Sicheng Wang; Xiao Chen; Jiacan Su
Journal:  EMBO Rep       Date:  2021-06-13       Impact factor: 9.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.